Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $1138.32
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a retail...
resTOR to be the first longevity clinic nationwide to offer the Company's blood-based epigenetic-genetic cardiovascular disease tests Cardio...
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr...
The Companyβs global patent portfolio includes granted patents in the United States, Europe, India, Australia, China and Hong Kong, and numerous...
HeartRiskβ’ Empowers Employers Who Adopt Cardio Diagnosticsβ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and...
This is the second CPT PLA code the American Medical Association (AMA) granted for the Companyβs AI-powered coronary heart disease tests. This...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.